Simon A. Williams - Concepedia

Author

Simon A. Williams

Johns Hopkins University

Also Known As

S Williams, Simon A Williams, Simon A. Williams, Simon Williams, Williams, Simon

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center The University of Texas MD Anderson Cancer Center Johns Hopkins Medicine Flinders University

About

Simon A. Williams is an author at Johns Hopkins University specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	636
2	Health Sciences	4	4	142
3	Engineering	3	3	42
4	Natural Sciences	2	2	42
5	Public Health	1	1	74

Simon A. Williams

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Simon A. Williams, Curtis A. Pettaway, Rendu Song, PubMed Chemoprevention StrategyApoptosisProteasome Inhibitor BortezomibCell DeathTumor Biology	2003	164
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Wenbiao Liu, Niels Reinmuth, Oliver Stoeltzing, PubMed InflammationCytokineCox-2 MrnaCell SignalingInterleukin-1 Beta	2003	135
Bortezomib Abolishes Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance via a p21-Dependent Mechanism in Human Bladder and Prostate Cancer Cells Laura M. Lashinger, Keyi Zhu, Simon A. Williams, Cancer Research	2005	108
The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Simon A. Williams, David J. McConkey PubMed Proteasome Inhibitor BortezomibMolecular BiologyP53 TranslocationCancer BiologyTumor Biology	2003	99
Risk of breast cancer in women with history of benign disease of the breast. M M Roberts, V Jones, R. A. Elton, BMJ Breast OncologyCancer PathologyEpidemiology Of CancerGynecologyPathology	1984	74
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-<i>cis</i>-retinoic acid in human malignant melanoma Yukihiko Kato, Brenda Salumbides, Xiao-Fei Wang, Molecular Cancer Therapeutics	2007	74
Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma Laura A Strickland, Jed Ross, Simon A. Williams, The Journal of Pathology	2009	67
Modulating paclitaxel bioavailability for targeting prostate cancer Srinivas K. Kumar, Simon A. Williams, John T. Isaacs, Bioorganic & Medicinal Chemistry MedicineTumor TargetingAnti-cancer AgentProstatic DiseasePharmacology	2007	51
Enzymatically active prostate‐specific antigen promotes growth of human prostate cancers Simon A. Williams, Christine Jelinek, Ivan V. Litvinov, The Prostate	2011	49
Prostate‐specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate‐targeted PSA/KLK2 double transgenic mice Simon A. Williams, Yi Xu, Angelo M. De Marzo, The Prostate	2010	46

Page 1